Excitotoxicity

Introduction

Excitotoxicity is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Excitotoxicity[@olney1969] is a pathological [@choi1992]
process in which neurons are damaged and destroyed by the overactivation of receptors for the excitatory neurotransmitter glutamate[@choi1992]. First described by John Olney in 1969 when he observed that monosodium glutamate[@choi1992] caused retinal neuron death in neonatal mice, excitotoxicity is now recognized as a central [@rothstein1995]
mechanism of neuronal injury in stroke, traumatic brain injury, and multiple neurodegenerative diseases including Alzheimer's Disease, amyotrophic [@lin1998]
lateral sclerosis (ALS), and Huntington's Disease [Olney, 1969](https://doi.org/10.1126/science.164.3880.719). The term captures the paradox that [@ikonomidou2002]
glutamate[@choi1992], the brain's most abundant excitatory neurotransmitter and an essential [@zeron2002]
mediator of synaptic plasticity and learning, becomes a potent neurotoxin when present in excess. [@kawahara2004]

Historical Discovery

Introduction

Excitotoxicity is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Excitotoxicity[@olney1969] is a pathological [@choi1992]
process in which neurons are damaged and destroyed by the overactivation of receptors for the excitatory neurotransmitter glutamate[@choi1992]. First described by John Olney in 1969 when he observed that monosodium glutamate[@choi1992] caused retinal neuron death in neonatal mice, excitotoxicity is now recognized as a central [@rothstein1995]
mechanism of neuronal injury in stroke, traumatic brain injury, and multiple neurodegenerative diseases including Alzheimer's Disease, amyotrophic [@lin1998]
lateral sclerosis (ALS), and Huntington's Disease [Olney, 1969](https://doi.org/10.1126/science.164.3880.719). The term captures the paradox that [@ikonomidou2002]
glutamate[@choi1992], the brain's most abundant excitatory neurotransmitter and an essential [@zeron2002]
mediator of synaptic plasticity and learning, becomes a potent neurotoxin when present in excess. [@kawahara2004]

Historical Discovery

John Olney's seminal 1969 study demonstrated that subcutaneous injection of monosodium glutamate[@choi1992] in neonatal mice produced acute neuronal necrosis in the arcuate nucleus of the [@lipton2006]
hypothalamus, along with retinal degeneration and obesity [Olney, 1969](https://doi.org/10.1126/science.164.3880.719). He coined the term [@bhatt2009]
"excitotoxicity" to describe this phenomenon. Dennis Choi extended this work in the 1980s by demonstrating that glutamate[@choi1992]-mediated neuronal death in cortical cell cultures was calcium-dependent and mediated [@hardingham2010]
primarily through NMDA receptors [@rothstein1995], [@bellingham2011]
establishing the calcium overload hypothesis that remains central to the field [Choi, 1992](https://doi.org/10.1002/neu.480231003). These discoveries [@li2011]
established the conceptual framework linking excessive glutamate[@choi1992]rgic transmission to [@wang2014]
neurodegeneration. [@parsons2014]

Molecular Mechanism

Glutamate Receptor Overactivation

Under pathological conditions such as ischemia, trauma, or chronic neurodegeneration, extracellular glutamate[@choi1992] concentrations rise dramatically due to excessive presynaptic release, impaired reuptake by astrocytic transporters, or reversal of glutamate[@choi1992] transporters during energy failure. This triggers sustained activation of three classes of ionotropic glutamate[@choi1992] receptors: [@lewerenz2015]

• NMDA receptors [@rothstein1995]: Highly calcium-permeable channels composed of GluN1 and GluN2 (A-D) subunits. Under normal conditions, a voltage-dependent magnesium block limits ion flux, but sustained depolarization relieves this block, permitting massive calcium entry. NMDA receptors are the primary mediators of excitotoxic calcium influx [Bhatt et al., 2009](https://doi.org/10.1016/j.abb.2008.12.009).
• AMPA[@lin1998] receptors: Mediate fast excitatory transmission. Most AMPA[@lin1998] receptors contain the GluA2 subunit, which renders them calcium-impermeable. However, neurons lacking GluA2 (due to impaired RNA editing or altered subunit expression) possess calcium-permeable AMPA[@lin1998] receptors that contribute directly to excitotoxic injury [Kawahara et al., 2004](https://doi.org/10.1038/427801a).
• Kainate receptors: Contribute to excitotoxicity through both ionotropic calcium flux and metabotropic signaling that modulates glutamate[@choi1992] release.

Calcium Overload and Downstream Cascades

The defining event in excitotoxicity is pathological elevation of intracellular calcium concentration, which rises from a resting level of approximately 100 nM to low micromolar ranges. This calcium overload activates multiple destructive cascades [Bhatt et al., 2009](https://doi.org/10.1016/j.abb.2008.12.009):

• calpains: Calcium-activated cysteine proteases that cleave cytoskeletal proteins (spectrin, MAP2), signaling molecules, and membrane receptors. Calpain activation is an early marker of excitotoxic injury and contributes to both necrotic and apoptotic cell death. Calpain also converts xanthine dehydrogenase to xanthine oxidase, generating reactive oxygen species.
• Calcineurin (protein phosphatase 2B): Calcium/calmodulin-dependent phosphatase that dephosphorylates the pro-apoptotic protein BAD, promoting its translocation to mitochondria and triggering apoptotic signaling.
• Neuronal nitric oxide synthase (nNOS): Calcium/calmodulin-dependent enzyme physically tethered to NMDA receptor[@rothstein1995] receptors] via PSD-95. [Overactivation produces excessive nitric oxide (NO), which reacts with superoxide to form peroxynitrite (ONOO^-), a potent oxidant that damages proteins, lipids, and DNA, and inhibits mitochondrial complex I and IV [Wang et al., 2014](https://doi.org/10.3390/ijms15046319).
• Mitochondrial permeability transition: Excessive mitochondrial calcium uptake triggers opening of the mitochondrial permeability transition pore (mPTP), collapsing the membrane potential, halting ATP synthesis, and releasing cytochrome c and apoptosis-inducing factor into the cytoplasm [Bhatt et al., 2009](https://doi.org/10.1016/j.abb.2008.12.009). This links calcium overload directly to both necrotic (energy failure) and apoptotic cell death pathways.

Synaptic vs. Extrasynaptic NMDA Receptor Dichotomy

A transformative concept in excitotoxicity research emerged from the work of Hardingham and Bading, who demonstrated that the subcellular location of NMDA receptor[@rothstein1995] receptor activation determines whether the outcome is neuroprotective or neurotoxic [Hardingham & Bading, 2010](https://doi.org/10.1038/nrn2911):

• Synaptic NMDA receptor](/proteins/nmda-receptor)[@rothstein1995] receptors (enriched in GluN2A subunits): Activation by physiological synaptic transmission engages the Ras-ERK-CREB pathway, promotes BDNF expression, upregulates antioxidant defenses (including thioredoxin and superoxide dismutase), and builds a neuroprotective "shield" against subsequent insults.
• Extrasynaptic NMDA[@rothstein1995] receptors (enriched in GluN2B subunits): Activated by glutamate[@choi1992] spillover during pathological conditions. Extrasynaptic activation shuts off CREB signaling, activates the FOXO transcription factor and pro-death gene expression, triggers mitochondrial depolarization, and promotes calpain-mediated cleavage of the phosphatase STEP, amplifying excitotoxic cascades [Hardingham & Bading, 2010](https://doi.org/10.1038/nrn2911).

Excitotoxicity in Stroke and Ischemia

Excitotoxicity[@olney1969] is the primary
mechanism of acute neuronal death following ischemic stroke. Within minutes of vessel occlusion, ATP depletion causes failure of the Na+/K+-ATPase
pump, neuronal depolarization, and uncontrolled release of glutamate[@choi1992] into the
extracellular space. Simultaneously, energy failure impairs astrocytic glutamate[@choi1992]
transporters (EAAT1/EAAT2) and may even reverse their function, further elevating extracellular glutamate[@choi1992] to neurotoxic concentrations exceeding 100 micromolar. The resulting NMDA receptor[@rothstein1995] receptor] overactivation, calcium influx, and mitochondrial
dysfunction produce a core of necrotic tissue (infarct) surrounded by a penumbral zone of delayed excitotoxic injury [Bhatt et al.,
2009](https://doi.org/10.1016/j.abb.2008.12.009).

Excitotoxicity in Alzheimer's Disease

In Alzheimer's Disease, amyloid-beta (Aβ oligomers directly enhance excitotoxic vulnerability through multiple mechanisms. Soluble
Aβ oligomers bind to GluN2B-containing extrasynaptic NMDA receptor[@rothstein1995] receptors], increasing extrasynaptic
calcium influx and inhibiting synaptic NMDA[@rothstein1995] receptor-dependent long-term potentiation (LTP). Abeta
also impairs glutamate[@choi1992] reuptake by astrocytes, elevating ambient glutamate[@choi1992] levels, and induces internalization of synaptic NMDA[@rothstein1995] receptors while
promoting extrasynaptic receptor trafficking [Li et al., 2011](https://doi.org/10.1523/JNEUROSCI.6542-10.2011). The resulting shift from
synaptic to extrasynaptic NMDA[@rothstein1995] receptor activation suppresses CREB-dependent survival gene expression
and promotes tau] hyperphosphorylation, linking excitotoxicity to tau] protein] pathology. This mechanistic understanding provides the
rationale for memantine use in moderate-to-severe AD.

Excitotoxicity in ALS

Glutamate excitotoxicity is a central pathogenic mechanism in amyotrophic lateral sclerosis. Motor neurons are particularly vulnerable due
to their large soma size, high density of calcium-permeable AMPA[@lin1998] receptors (resulting from low GluA2
expression), and high metabolic demands. A critical feature of ALS pathology is the loss of the astrocytic glutamate[@choi1992] transporter EAAT2 (GLT-1), which normally clears approximately 90% of synaptic glutamate[@choi1992]. Post-mortem studies show a 30-95% reduction in EAAT2 protein in the motor cortex and spinal cord of ALS
patients, attributable to aberrant RNA splicing, oxidative damage, and caspase-3-mediated cleavage [Rothstein et al.,
1995](https://doi.org/10.1016/0306-4522(95)00064-9); [Lin et al., 1998](https://doi.org/10.1016/s0896-6273(00)80997-6). Riluzole, the first
FDA-approved ALS therapy, extends median survival by 2-3 months through multiple anti-excitotoxic mechanisms: inhibition of presynaptic
glutamate[@choi1992] release, blockade of voltage-gated sodium channels, and modest antagonism of NMDA[@rothstein1995] receptors [Bellingham, 2011](https://doi.org/10.2165/11536200-000000000-00000).

Excitotoxicity in Huntington's Disease

Medium spiny neurons (MSNs) of the striatum, the cell population most vulnerable in Huntington's Disease, are exquisitely sensitive to
NMDA[@rothstein1995] receptor-mediated excitotoxicity. Mutant huntingtin (mHTT) enhances excitotoxic vulnerability
through several mechanisms: mHTT directly interacts with GluN2B-containing NMDA receptor[@rothstein1995] receptors],
potentiating receptor currents; mHTT impairs binding to PSD-95, freeing PSD-95 to stabilize more GluN2B-containing receptors at the synapse;
mHTT sensitizes mitochondria to calcium-induced depolarization, lowering the threshold for mPTP opening; and mHTT disrupts EAAT2 expression
in surrounding astrocytes [Bhatt et al., 2009](https://doi.org/10.1016/j.abb.2008.12.009); [Zeron et al.,
2002](https://doi.org/10.1016/S0896-6273(02)00615-3). Injection of the NMDA[@rothstein1995] receptor agonist
quinolinic acid into the rodent striatum faithfully reproduces the selective MSN loss and chorea-like motor phenotype of HD, further
supporting the excitotoxicity hypothesis.

Therapeutic Approaches

| Agent | Mechanism | Indication | Status | Key Outcome |
|---|---|---|---|---|
| Memantine | Low-affinity, voltage-dependent, open-channel NMDA[@rothstein1995] receptor blocker; preferentially blocks tonically activated extrasynaptic receptors | Moderate-to-severe AD | FDA-approved (2003) | Modest cognitive benefit; does not disrupt normal synaptic transmission |
| Riluzole | Inhibits glutamate[@choi1992] release; blocks voltage-gated Na+ channels; weak NMDA[@rothstein1995] antagonism | ALS | FDA-approved (1995) | Extends median survival by 2-3 months |
| Selfotel (CGS 19755) | Competitive NMDA[@rothstein1995] antagonist | Acute stroke | Failed Phase III | No efficacy; psychotomimetic side effects; trial stopped for futility |
| Aptiganel (Cerestat) | Non-competitive NMDA[@rothstein1995] channel blocker | Acute stroke | Failed Phase III | Worse outcomes in treatment group; hypertension and sedation |
| Gavestinel (GV150526) | Glycine-site NMDA[@rothstein1995] antagonist | Acute stroke | Failed Phase III (GAIN trial) | No benefit vs. placebo at 3 months |
| Perampanel | Selective non-competitive AMPA[@lin1998] receptor antagonist | Epilepsy; ALS trials | FDA-approved for epilepsy; investigational for ALS | Reduced seizure frequency; ALS trials ongoing |
| Ceftriaxone | Upregulates EAAT2 expression | ALS | Failed Phase III | Preclinical promise; no survival benefit in clinical trial |

Why NMDA Antagonists Failed in Stroke Trials

Despite strong preclinical evidence, over 30 clinical trials of NMDA[@rothstein1995] receptor antagonists in acute stroke failed to demonstrate benefit [Bhatt et al., 2009](https://doi.org/10.1016/j.abb.2008.12.009); [Ikonomidou & Turski, 2002](https://doi.org/10.1016/S1474-4422(02)00164-3). Multiple factors contributed to this failure:

The success of memantine in Alzheimer's Disease, by contrast, demonstrates that low-affinity, voltage-dependent NMDA[@rothstein1995] blockade can provide clinical benefit by preferentially blocking pathological tonic receptor activation while sparing phasic synaptic transmission [Lipton, 2006](https://doi.org/10.1038/nrn1703).

Current Research Directions

Research continues to refine therapeutic strategies based on mechanistic understanding of excitotoxicity:

• GluN2B-selective antagonists: Compounds such as ifenprodil derivatives aim to block extrasynaptic GluN2B-containing receptors while preserving synaptic GluN2A signaling.
• EAAT2 upregulation: Small-molecule EAAT2 activators are being developed to enhance glutamate[@choi1992] clearance in ALS and other conditions.
• Combination therapy: Multi-target approaches combining glutamate[@choi1992] modulation with antioxidants or mitochondrial protectants aim to address the interconnected cascades downstream of calcium homeostasis disruption.
• Precision timing: Neuroprotective strategies are being paired with rapid stroke intervention (thrombectomy, thrombolysis) to deliver anti-excitotoxic agents within the narrow therapeutic window.
• [Memantine](/therapeutics/memantine)

Brain Atlas Resources

• Allen Human Brain Atlas: [Excitotoxicity expression search](https://human.brain-map.org/microarray/search/show?search_term=Excitotoxicity)
• Allen Mouse Brain Atlas: [Excitotoxicity search](https://mouse.brain-map.org/search/index.html?query=Excitotoxicity)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Excitotoxicity developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Excitotoxicity)

Background

The study of Excitotoxicity has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Excitotoxicity discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving Excitotoxicity discovered through SciDEX knowledge graph analysis: